黄家强

博士 、教授

基本信息

办公电话：10-51684348 电子邮件： jqhuang@bjtu.edu.cn
通讯地址：北京市海淀区西直门外上园村3号北京交通大学生命科学与生物工程研究院 邮编：100044

教育背景

医学博士，1997年 华中科大同济医学院（原同济医科大学)

工作经历

1993 - 1994年：华中科大同济医学院基础医学院免疫室，助教;

1997 - 1999年：北京大学医学部免疫系, 人类基因疾病中心，博士后；

1999 - 2004年：美国国家癌症研究所（NCI）, 分子免疫调节实验室， 访问学者(1999-2001), 科学家 (2001-2004, Basic Research Program, SAIC-Frederick)；

2004 - 2006年：美国约翰霍普金斯大学医学院， Faculty member，助理研究员； 

2006 -2 011年：美国Qiagen-SABiosciences，资深科学家；

2011-             ： 交通大学理学院生命科学与生物工程研究院， 教授；

2013-             ： 美国NCI， Cancer & Inflammation Program, 合作研究员

研究方向

  • 生物化学与分子生物学
  • 生物信息学

招生专业

  • 生物学硕士

科研项目

1.    交大—诺森项目联合转化研究创新中心（S18L00290）；2018-2028；2，000万元；项目负责人。

2.    骨髓锌指1的表观调控在胃癌化疗敏感性中与金属硫蛋白2A 相互作用机制。自然科学基金面上（81872021）；67万；子课题负责。

3.    免疫力科研检测（KSL18029530）；2018-2019；3万元；项目负责人。

4.    河南“1125聚才计划”创新创业领军团队；2017-2020；300万元；领军人才，项目负责人。

5.    阿尔茨海默病检测试剂盒研发（KSL18004530）；166万；参与。            

6.    Funded in part by Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E （2013.5-  ）。

7.    Supported in part by the Intramural Research Program of the NCI, NIH （2013.5- ）。

8.    耐药结核菌检测方法的研究（KSL14010530）；2014-2017；50万元；项目负责人。

9.    恶性肿瘤发病机制及转化研究教育部重点实验室开放基金: 金属硫蛋白2A（MT2A）在胃癌中的表观调控及其功能应用研究(开放-8); 2014-2016；10万元；主持。

10.  以生物技术药为主的综合性新药研发技术大平台建设（2013ZX09301301001-005）；"重大新药创制”国家科技重大专项；1300.00万元；2013-2015 ；子课题负责人（680万元）。

11.  AMP-18在胃癌中功能机制研究及其临床应用价值（人才基金）; 2012-2015；15万元；主持

教学工作

《遗传学》（本科生);
《表观遗传学》（双语授课）（本科生);
《生命科学纵横》（本科生);
《分子细胞免疫学》（双语授课）（研究生），
 1994-1997年 华中科大同济医学院，《免疫学》（研究生），《医学免疫学》（本科生）。
 1997-1999年 北京大学, 《医学分子免疫学》（研究生），《医学免疫学》（本科生）

论文/期刊



  1. Selected SCI Publications （2000年之后）: 

    1.    CpG Methylation-Driven Pleiotropic Spliced Isoforms of PRSS3 Facilitate Gastric Intratumor Heterogeneity and Metastasis. Pang M, Xu H, Li D, Zhang M, Chen D, Tian R, Gu J, Alimu N, Wang E, Zhou Z, Li X, Peng Q, He Y, Lin S, Guo M, Huang J. Cancer Sci. 2025 Oct 29. IF: 4.3 Q2

    2.    Targeting the PRSS3-PAR2-ERK1/2 axis inhibits malignancy and regulates chemosensitivity and resistance through ferroptosis in breast cancer.Tian R, Li D, Lan C, Xu H, Ma X, Chen D, Wang E, Liu J, Tian T, Gao H, Huang J. Free Radic Biol Med. 2025 Oct 3;241:642-658. IF: 8.2 Q1

    3.    Construction of a tumor immune microenvironment-related risk scoring model for prognosis of hepatocellular carcinoma. Li X, Qin Z, Chen H, Chen D, Alimu N, Li D, Cheng X, Yan Q, Zhang L, Liu X, Zhou Z, Zhu J, Ma H, Pei X, Xu H, Huang J. Int J Immunopathol Pharmacol. 2025 Jan-Dec;39:3946320251333975. IF: 2.6 Q2 

    4.    SNP-based and haplotype-based genome-wide association on drug dependence in Han Chinese. Xu H, Kang Y, Liang T, Lu S, Xia X, Lu Z, Hu L, Guo L, Zhang L, Huang J, Ye L, Jiang P, Liu Y, Xinyi L, Zhai J, Wang Z, Liu Y. BMC Genomics. 2024 Mar 6;25(1):255. IF: 3.7 Q2

    5.    Cancer Stem Cell Biomarkers in the Nervous System. Li X, Huang J, Kang Y, Cheng X, Yan Q, Zhang L, Fan J, Xu H. Front Biosci (Landmark Ed). 2023 Dec 29;28(12):362. IF: 3.1 Q3

    6.    The beneficial effects of commensal E. coli for colon epithelial cell recovery are related with Formyl peptide receptor 2 (Fpr2) in epithelial cells. Chen K, McCulloch J, Das Neves R, Rodrigues G, Hsieh WT, Gong W, Yoshimura T, Huang J, O'hUigin C, Difilippantonio S, McCollum M, Jones G, Durum SK, Trinchieri G, Wang JM. Gut Pathog. 2023 Jun 15;15(1):28. IF: 4.0 Q1

    7.    UHRF1/DNMT1-MZF1 axis-modulated intragenic site-specific CpGI methylation confers divergent expression and opposing functions of PRSS3 isoforms in lung cancer. Lin S, Xu H, Qin L, Pang M, Wang Z, Gu M, Zhang L, Zhao C, Hao X, Zhang Z, Ding W, Ren J, Huang J. Acta Pharm Sin B. 2023 May;13(5):2086-2106. IF: 14.6 Q1

    8.    New genetic and epigenetic insights into the chemokine system: the latest discoveries aiding progression toward precision medicine. Xu H, Lin S, Zhou Z, Li D, Zhang X, Yu M, Zhao R, Wang Y, Qian J, Li X, Li B, Wei C, Chen K, Yoshimura T, Wang JM, Huang J. Cell Mol Immunol. 2023 Jul;20(7):739-776. IF: 19.8 Q1

    9.    Beneficial effects of postoperative radiotherapy for IIIA‑N2 non‑small cell lung cancer after radical resection analysed using the propensity score‑matching method. Tian C, Liu G, Xu Y, Xia G, Zhang T, Huang J, Liu F, Li B. Oncol Lett. 2023 Apr 5;25(5):205. IF: 2.2 Q3 

    10.  Developmental and homeostatic signaling transmitted by the G-protein coupled receptor FPR2. Chen K, Gong W, Huang J, Yoshimura T, Ming Wang J. Int Immunopharmacol. 2023 May;118:110052. IF: 4.7 Q1

    11.  CpG Site-Specific Methylation-Modulated Divergent Expression of PRSS3 Transcript Variants Facilitates Nongenetic Intratumor Heterogeneity in Human Hepatocellular Carcinoma. Lin S, Xu H, Pang M, Zhou X, Pan Y, Zhang L, Guan X, Wang X, Lin B, Tian R, Chen K, Zhang X, Yang Z, Ji F, Huang Y, Wei W, Gong W, Ren J, Wang JM, Guo M, Huang J. Front Oncol. 2022 Apr 11;12:831268. IF: 3.3 Q2 

    12.  Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: a preferential benefit for squamous cell carcinoma. Tian C, Liu G, Xu Y, Xia G, Zhang T, Huang J, Jiang H, Ming Wang J, Li B. Radiol Oncol. 2020 Dec 3;55(1):66-76. IF: 2.2 Q2

    13.  Differential MUC22 expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma. Lin S, Tian C, Li J, Liu B, Ma T, Chen K, Gong W, Wang JM, Huang J. Oncol Rep. 2021 May;45(5). IF: 3.9 Q2

    14.  Requirement of CRAMP for mouse macrophages to eliminate phagocytosed E. coli through an autophagy pathway. Chen K, Yoshimura T, Gong W, Tian C, Huang J, Trinchieri G, Wang JM. J Cell Sci. 2021 Mar 8;134(5). IF: 3.6 Q2 

    15.  The G-Protein Coupled Formyl Peptide Receptors and Their Role in the Progression of Digestive Tract Cancer. Tian C, Chen K, Gong W, Yoshimura T, Huang J, Wang JM. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820973280. IF: 2.8 Q2

    16.  FAM3D is essential for colon homeostasis and host defense against inflammation associated carcinogenesis. Liang W, Peng X, Li Q, Wang P, Lv P, Song Q, She S, Huang S, Chen K, Gong W, Yuan W, Thovarai V, Yoshimura T, O'huigin C, Trinchieri G, Huang J, Lin S, Yao X, Bian X, Kong W, Xi J, Wang JM, Wang Y. Nat Commun. 2020 Nov 20;11(1):5912. IF: 15.7 Q1

    17.  Tumor suppressor ATP4B serve as a promising biomarker for worsening of gastric atrophy and poor differentiation. Pan Y, Wang X, He Y, Lin S, Zhu M, Li Y, Wang J, Wang J, Ma X, Xu J, Yang L, Yang G, Huang J, Lu Y, Sheng J. Gastric Cancer. 2021 Mar;24(2):314-326. IF: 5.1 Q1

    18.  Distinct contributions of cathelin-related antimicrobial peptide (CRAMP) derived from epithelial cells and macrophages to colon mucosal homeostasis. Chen K, Yoshimura T, Yao X, Gong W, Huang J, Dzutsev AK, McCulloch J, O'hUigin C, Bian XW, Trinchieri G, Wang JM. J Pathol. 2021 Mar;253(3):339-350. IF: 5.2 Q1 

    19.  Analysis of Continuous Mutation and Evolution on Circulating SARS-CoV-2. Yu JM, Zhang LS, Fu YH, Ji FM, Xu HL, Huang JQ, Peng XL, Zheng YP, Zhang Y, He JS. Evol Bioinform Online. 2020 Oct 1;16:1176934320954870. IF: 1.5 Q4

    20.  A Critical Role of Formyl Peptide Receptors in Host Defense against Escherichia coli. Zhang M, Gao JL, Chen K, Yoshimura T, Liang W, Gong W, Li X, Huang J, McDermott DH, Murphy PM, Wang X, Wang JM. J Immunol. 2020 May 1;204(9):2464-2473. IF: 3.4 Q2

    21.  Epigenetic downregulation of MUC17 by H. pylori infection facilitates NF-κB-mediated expression of CEACAM1-3S in human gastric cancer.Lin S, Zhang Y, Hu Y, Yang B, Cui J, Huang J, Wang JM, Xing R, Lu Y. Gastric Cancer. 2019 Sep;22(5):941-954. IF: 5.1 Q1

    22.  Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A.Lin S, Wang X, Pan Y, Tian R, Lin B, Jiang G, Chen K, He Y, Zhang L, Zhai W, Jin P, Yang L, Li G, Wu Y, Hu J, Gong W, Chang Z, Sheng JQ, Lu Y, Wang JM, Huang J. Clin Cancer Res. 2019 Feb 1;25(3):1050-1062. IF: 10.2 Q1 

    23.  The Antimicrobial Peptide CRAMP Is Essential for Colon Homeostasis by Maintaining Microbiota Balance. Yoshimura T, McLean MH, Dzutsev AK, Yao X, Chen K, Huang J, Gong W, Zhou J, Xiang Y, H Badger J, O'hUigin C, Thovarai V, Tessarollo L, Durum SK, Trinchieri G, Bian XW, Wang JM. J Immunol. 2018 Mar 15;200(6):2174-2185.IF: 3.4 Q2

    24.  Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib. Wang X, Chen K, Yu Y, Xiang Y, Kim JH, Gong W, Huang J, Shi G, Li Q, Zhou M, Sayers T, Tewary P, Gao B, Wang JM. Oncotarget. 2017 Nov 21;8(65):109068-109078.

    25.  Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma.Lin B, Zhou X, Lin S, Wang X, Zhang M, Cao B, Dong Y, Yang S, Wang JM, Guo M, Huang J. J Mol Med (Berl). 2017 Nov;95(11):1237-1249. IF: 4.2 Q1

    26.  A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus. Jiao YY, Fu YH, Yan YF, Hua Y, Ma Y, Zhang XJ, Song JD, Peng XL, Huang J, Hong T, He JS. Antiviral Res. 2017 Aug; 144:57-69. IF: 4.0 Q1

    27. Silencing of ATP4B of ATPase H(+)/K(+) Transporting Beta Subunit by Intragenic Epigenetic Alteration in Human Gastric Cancer Cells.Lin S, Lin B, Wang X, Pan Y, Xu Q, He JS, Gong W, Xing R, He Y, Guo L, Lu Y, Wang JM, Huang J. Oncol Res. 2017 Mar 13;25(3):317-329. IF: 4.1 Q2

    28.  The G-protein coupled chemoattractant receptor FPR2 promotes malignant phenotype of human colon cancer cells.Xiang Y, Yao X, Chen K, Wang X, Zhou J, Gong W, Yoshimura T, Huang J, Wang R, Wu Y, Shi G, Bian X, Wang J. Am J Cancer Res. 2016 Nov 1;6(11):2599-2610. IF: 2.9 Q2 

    29. Copy number variations of HLA-I and activation of NKp30 pathway determine the sensitivity of gastric cancer cells to the cytotoxicity of natural killer cells. Xing R, Li L, Chen L, Gao Z, Wang H, Li W, Cui J, Tian G, Liang Q, Yu J, Sung JJ, Luo G, Gao H, Xu X, Yang H, Wang J, Zhang X, Wang JM, Huang J, Yu Y, Wang J, Lu Y. Oncogene. 2016 May 19; 35(20):2584-91. IF: 7.3 Q1

    30.  Epigenetic Upregulation of Metallothionein 2A by Diallyl Trisulfide Enhances Chemosensitivity of Human Gastric Cancer Cells to Docetaxel Through Attenuating NF-κB Activation.Pan Y, Lin S, Xing R, Zhu M, Lin B, Cui J, Li W, Gao J, Shen L, Zhao Y, Guo M, Wang JM, Huang J, Lu Y. Antioxid Redox Signal. 2016 May 20;24(15):839-54. IF: 6.1 Q1

    31.  The role of microRNA-133b and its target gene FSCN1 in gastric cancer. Guo L, Bai H, Zou D, Hong T, Liu J, Huang J, He P, Zhou Q, He J. J Exp Clin Cancer Res. 2014 Nov 30;33(1):99. IF: 12.8 Q1

    32.  The formylpeptide receptor 2 (Fpr2) and its endogenous ligand cathelin-related antimicrobial peptide (CRAMP) promote dendritic cell maturation. Chen K, Xiang Y, Huang J, Gong W, Yoshimura T, Jiang Q, Tessarollo L, Le Y, Wang JM. J Biol Chem. 2014 Jun 20;289(25):17553-63. IF: 3.9 Q2

    33.  Metallothionein 2A inhibits NF-κB pathway activation and predicts clinical outcome segregated with TNM stage in gastric cancer patients following radical resection. Pan Y, Huang J, Xing R, Yin X, Cui J, Li W, Yu J, Lu Y. J Transl Med. 2013 Jul 19;11:173. IF: 7.5 Q1

    34. IL-7Rα deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis. R Kibe 1, S Zhang, D Guo, L Marrero, F Tsien, P Rodriguez, S Khan, A Zieske, J Huang, W Li, S K Durum, T Iwakuma, Y Cui. Cell Death Differ. 2012 Jul;19(7):1139-51. IF: 15.4 Q1

    35.  TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Hamano R, Huang J, Yoshimura T, Oppenheim JJ, Chen X. Eur J Immunol. 2011 Jul;41(7):2010-20. IF: 5.6 Q2 

    36.  Lsh, chromatin remodeling family member, modulates genome-wide cytosine methylation patterns at nonrepeat sequences. Tao Y, Xi S, Shan J, Maunakea A, Che A, Briones V, Lee EY, Geiman T, Huang J, Stephens R, Leighty RM, Zhao K, Muegge K. Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5626-31. IF: 9.4 Q1

    37.  B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. Zhu G, Augustine MM, Azuma T, Luo L, Yao S, Anand S, Rietz AC, Huang J, Xu H, Flies AS, Flies SJ, Tamada K, Colonna M, van Deursen JM, Chen L. Blood. 2009 Feb 19;113(8):1759-67. IF: 23.1 Q1 

    38.  Regulation of the leucocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation. Huang J, Chen K, Huang J, Gong W, Dunlop NM, Howard OM, Bian X, Gao Y, Wang JM. Carcinogenesis. 2009 Feb;30(2):348-55. IF: 5.3 Q2

    39.  Role of the intracellular domain of IL-7 receptor in T cell development. Jiang Q, Huang J, Li WQ, Cavinato T, Keller JR, Durum SK. J Immunol. 2007 Jan 1;178(1):228-34. IF: 6.3 Q2

    40.  Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Wang LH, Yang XY, Zhang X, An P, Kim HJ, Huang J, Clarke R, Osborne CK, Inman JK, Appella E, Farrar WL. Cancer Cell. 2006 Dec;10(6):487-99. IF: 44.5 Q1

    41.  Lsh, an epigenetic guardian of repetitive elements. Huang J, Fan T, Yan Q, Zhu H, Fox S, Issaq HJ, Best L, Gangi L, Munroe D, Muegge K. Nucleic Acids Res. 2004 Sep 24;32(17):5019-28. IF: 13.1 Q1 

    42.  Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells.Wang LH, Yang XY, Zhang X, Huang J, Hou J, Li J, Xiong H, Mihalic K, Zhu H, Xiao W, Farrar WL. Immunity. 2004 Feb;20(2):205-18. IF: 26.3 Q1

    43. Lsh, a modulator of CpG methylation, is crucial for normal histone methylation. Yan Q*, Huang J*, Fan T, Zhu H, Muegge K. EMBO J. 2003 Oct 1;22(19):5154-62. IF:11 Q1 （共一）

    44. Lsh-deficient murine embryonal fibroblasts show reduced proliferation with signs of abnormal mitosis. Fan T, Yan Q, Huang J, Austin S, Cho E, Ferris D, Muegge K. Cancer Res. 2003 Aug 1;63(15):4677-83. IF: 7.9 Q1

    45. Bax deficiency partially corrects interleukin-7 receptor alpha deficiency. Khaled AR, Li WQ, Huang J, Fry TJ, Khaled AS, Mackall CL, Muegge K, Young HA, Durum SK. Immunity. 2002 Nov;17(5):561-73. IF: 20.6 Q1

    46. Cutting edge: Histone acetylation and recombination at the TCR gamma locus follows IL-7 induction. Huang, J., Durum, S. K., and Muegge, K. J. Immunol (cutting-edge). 2001; 167: 6073-6077. IF: 7.3

    47. Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Han W, Lou Y, Tang J, Zhang Y, Chen Y, Li Y, Gu W, Huang J, Gui L, Tang Y, Li F, Song Q, Di C, Wang L, Shi Q, Sun R, Xia D, Rui M, Tang J, Ma D. Biochem J. 2001 Jul 1; 357(Pt 1):127-35. IF: 4.3

    48. Control of chromatin accessibility for V(D)J recombination by interleukin 7. Huang, J. & Muegge, K. J. Leukoc. Biol. 2001; 69:907-11. IF: 4.5

专著/译著

参与编写：

苏娜  沈关心 主编《抗体工程》科学出版社  1996

杨锡强 主编《儿童免疫学》 人民卫生出版社 2001


专利


  1. 一种复方镇痛药; Patent No: ZL 94 1 08418.3;  International paten classic No: A61K 31/55.
  2. Chemokine-like factors (CKLFs) with chemotactic and hematopoietic stimulating activities; International patent classic No: C07K 14/52, C12N 15/19, A61K 38/19.
  3. Nucleic acid molecule encoding chemokine-like factor 1 (CKLF1); United States Patent 6800454.
  4. MT2A基因组蛋白乙酰化修饰检测试剂盒及引物对; 专利号：ZL201510598585.6。
  5. 一种用于肝癌诊断、化疗与预后检测的分子标记物及试剂盒；专利号：ZL201710679242.1。
  6. 一种用于肿瘤诊断与预后检测的分子标志物及其检测引物和试剂盒；专利号：ZL201710679293.4。
  7. 一种基于ATP4B基因体DNA的表观修饰检测引物对及试剂盒; 专利号：ZL201610979087.0.
  8. 一种用于非小细胞肺癌早期诊断、治疗与预后检测的分子分型甲基化标志物及试剂盒发明专利; 专利号：ZL202011517819.7。
  9. MUC22基因启动子区相关的组蛋白修饰分析引物对及检测试剂盒；CN202011621103.1。
  10. 一种肺癌诊断、化疗或预后检测的分子标记物及其应用；CN202210132512.8。
  11. 一种用于肺腺癌非创早期诊断、药效评估的分子标志物及试剂盒；CN202210133444.7。
  12. 一种用于肿瘤分子分型、治疗用药评估的分子标志物及其检测引物和试剂盒， CN202110016858.7。
  13. 一种应用于环境污染致癌风险评估的试剂盒， ZL202111336575.7。


软件著作权

获奖与荣誉

社会兼职